ABSTRACT
Objective To explore clinical efficacy of elephantiasis myogenic cream for treatment of chronic refractory skin ulcer. Methods A total of 91 chronic refractory skin ulcer patients were randomized into the treatment group (n=46) and the control group (n=45) by random number table method. Patients of control group were treated with conventional debridement, while the treatment group were treated with elephantiasis myogenic cream. The two groups were treated for 4 weeks. Clinical curative effect was evaluated after treatment. The pain score at the times of debridement and ulcer wound healing time of the two groups were compared. The FGF-2, VEGF and fiber connection (Fn) of wound secretion of the two groups before and after treatment were compared. Results Total effective rate of treatment group was 87.0％ (40/46), which was significantly higher than the control group 66.7％ (30/45), and the difference was statistically significant (χ2=5.275, P=0.022). The pain score at the time of 2 w and 4 w after treatment in the treatment group were significantly lower than those in the control group (t value were 10.456, 12.266, all Ps<0.01). After treatment, ulcer wound healing time in the treatment group were significantly lower than those in the control group (t=2.911, P=0.002). After treatment, the FGF-2 (7.72 ± 0.58 ng/ml vs. 6.37 ± 0.50 ng/ml, t=11.881), VEGF (24.85 ± 5.63 ng/ml vs. 18.75 ± 4.51 ng/ml, t=5.697) and Fn (4.15 ± 0.42 ng/ml vs. 3.47 ± 0.38 ng/ml, t=8.093) of wound secretion in the treatment group were significantly higher than those in the control group (P<0.05).There were no serious adverse reaction of the two groups during treatment. Conclusions The elephantiasis myogenic cream for treatment of chronic refractory skin ulcer has a good efficacy and low adverse reactions, can relieve patients' pain, improve the wound heal, reduce heal times.
ABSTRACT
Translational medicine, a kind of medical scientific practice oriented by patients'demands, emphasizes that basic theoretical study helps enhance clinical effect, transform into new drugs as well as meet major needs of social development and human health. It follows disciplinary development rules of TCM, persists in five-in-one (theory-clinic-new drug-experiment-evidence based) innovative new mode of TCM translational development, accelerates internal transformation of research findings, and promotes clinical effect and disciplinary development driven by the oretical innovation of collateral disease. In terms of the oretical research, establishment of new discipline of TCM collateral disease theory has become a practitioner and typical representative for promotion of TCM industry development. Important position and guiding role of theoretical innovation in disciplinary development has been valued. Systematically constructing ″collateral disease treatment based on syndrome differen?tiation″ and ″meridian-collateral theory″ lay a theoretical foundation for establishment of the discipline. With regard to clinical research, under the guidance of TCM theory-collateral disease theory, systematic researches on Chinese medical pathogenesis, intervention strategy and effective formula of major diseases are conducted; series of innovative Chinese medicines are developed. Through pharmacody?namics study, relevant action mechanisms are investigated and revealed in- depth. Evidence- based medical researches prove that representative activating-collateral drugs developed under guidance of collateral disease theory have great application values in prevention and treatment of major refractory diseases such as ischemic cardio-cerebrovascular disease, arrhythmia, chronic heart failure, influenza, tumors and diabetes, bringing about significant economic and social benefits. In this way, international cooperation is promoted and internationalization process of innovative Chinese medicine is accelerated. USA FDA phase-Ⅱ clinical research of Lianhua Qingwen Capsules has been successfully launched. Guided by inheritance and innovation of conventional theory of TCM, the new five- in- one mode of development is established. Such a mode conforms to disciplinary development rules of TCM, suffi?ciently exerts core driving effect of TCM theory, realizes combination of theoretical innovation with clinical practice, specialty construction with disciplinary development and clinical research with original new drug, as well as powerfully promotes progress of TCM collateral disease discipline.
ABSTRACT
Objective To observe the efficacy and adverse events of L-asparaginasum plus DICE regimen in the treatment of relapsed and refractory non-Hodgkin's lymphoma (NHL). Methods Thirty-one patients with relapsed and refractory NHL were treated with L-asparaginasum plus DICE regimen. Each patient was scheduled to receive 2 to 6 cycles.Results Among the 31 assessable patients,11 (35.5 ％) achieved a complete remission (CR),14(45.2 ％) got a partial remission (PR),2 were stable,4 were progressive.The overall response (CR + PR) rate was 80.7 ％.The median survival was 8 months (rang:2-38 months).The 1-year survival rate was 43.3 ％,the 2-year survival rate was 32.5 ％.The main adverse events were myelosuppression,digestive tract reaction,allergy and edema.No treatment-related death was observed.Conclusion The L-asparaginasum plus DICE regimen is effective and safe for the relapsed and refractory NHL.
ABSTRACT
Objective To explore the effective treatment with regimen of remission induction for relapsed/refractory precursor lymphocytic leukemia/lymphoma patients. Methods 6 patients with relapsed/refractory precursor lymphocytic leukemia/lymphoma including 2 acute lymphocytic leukemia, 4 lymphoblast lymphoma and 1 hybrid acute leukemia were treated by combination of CAG regimen with L-asparaginase (L-Asp) and prednisone (PDN). Results All patients responded to the regimen, in which 6/7 (85.7 %)patients achieved complete remission and 1/7 (14.3 %) patient achieved partial remission after one course.Light adverse events coursed by the regimen could be tolerated. Conclusion The regimen consisting of CAG, PDN and L-Asp is worth exploring for relapsed/refractory precursor lymphocytic leukemia/lymphoma.
ABSTRACT
Chief doctor ZHANG Ren has been engaged in acupuncture practice and literature research for about forty years, with abundant knowledge and clinical experience, particularly in the application of needling techniques. This article presents his experience in the treatment of refractory diseases.
ABSTRACT
It’s well known that bad health leads to serious illness. The fight against diseases demands the reinforcement of the body. This is particularly true in the case of treating refractory diseases, such as AIDS. The traditional medicine reinforces the body by invigorating “qi” and reriching the blood, and regulating the functions of five “zang”-organs. The treatment includes: 1. Invigorating “qi” and tonifying the blood. Recipe (R): Eight precious ingredients decoction; 2. Promoting flow of “qi” and blood circulation. R: Modified decoction of four ingredients; 3. Nourishing “yin” and clearing away the heat. Remedies (Re): Badix Trichosanthis, etc; 4. Removing heat from the blood to stop bleeding. R: Decoction of Rhinoceros Horn and Rehmania, ect; 5. Nourishing and tonifying “yin”. R: Decoction for relieving dryness of the lung, etc; 6. Clearing away heat and toxic materials. R: universal relief decoction for disinfection, etc; 7. Warming the hi and the kidney. R: Bolus for tonifying the kidney “qi”, etc